Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …
clinical features, but current knowledge gaps, including validation of biomarkers and …
[HTML][HTML] COVID-19-associated neurological disorders: the potential route of CNS invasion and blood-brain barrier relevance
A Achar, C Ghosh - Cells, 2020 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human
coronavirus that has sparked a global pandemic of the coronavirus disease of 2019 (COVID …
coronavirus that has sparked a global pandemic of the coronavirus disease of 2019 (COVID …
Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis
Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …
Humoral-and T-cell–specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies
Background and Objectives To evaluate the immune-specific response after full severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination of patients with …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination of patients with …
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …
available in the past years. There is a need for a reference tool compiling current data to aid …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies
G Luna, P Al**, J Burman, K Fink… - JAMA …, 2020 - jamanetwork.com
Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS)
have been associated with an increased risk of infections vs injectable therapies interferon …
have been associated with an increased risk of infections vs injectable therapies interferon …
COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies
AT Reder, D Centonze, ML Naylor, A Nagpal… - CNS drugs, 2021 - Springer
Abstract Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target
immunity and have the potential to increase the risk of severe acute respiratory syndrome …
immunity and have the potential to increase the risk of severe acute respiratory syndrome …
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic
The emergence of novel coronavirus 2019 (COVID-19) 1 and the subsequent pandemic
present a unique challenge to neurologists managing patients with multiple sclerosis (MS) …
present a unique challenge to neurologists managing patients with multiple sclerosis (MS) …
[HTML][HTML] Alterations of oligodendrocyte and myelin energy metabolism in multiple sclerosis
E López-Muguruza, C Matute - International journal of molecular sciences, 2023 - mdpi.com
Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system
(CNS), characterized by demyelination and neurodegeneration. Oligodendrocytes play a …
(CNS), characterized by demyelination and neurodegeneration. Oligodendrocytes play a …